Chile Pharmaceuticals and Healthcare Report Q4 2017
BMI View: The non-profit group Knowledge Ecology International has put pressure on the Chilean government to use its authority to grant compulsory licences for the branded prostate cancer drug, enzalutamide (Xtandi) and on sofosbuvir-based combination drugs for the treatment of hepatitis C (HCV).
The Chilean government will need to tread carefully in considering the controversial petition, but so too will Astellas Pharma and Gilead Sciences if the pressure becomes sufficient to warrant a response.
Headline Expenditure Projections
Pharmaceuticals: From CLP2.4trn (USD3.5bn) in 2016 to CLP2.6trn (USD3.9bn) in 2017; +8.3% in local currency terms and +9.3% in US dollar terms. Forecast in US dollar slightly increased compared to last quarter.
Healthcare: From CLP14.1trn (USD20.8bn) in 2016 to CLP15.5trn (USD23.1bn) in 2017; +9.9% rise in local currency terms and +10.9% in US dollar terms. Forecast in US dollar slightly increased compared to last quarter.